• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症和营养标志物在新辅助化疗和 D2 淋巴结清扫术治疗胃癌患者生存预测中的临床价值和应用。

The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy.

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Haidian District, 100142, Beijing, China.

出版信息

Gastric Cancer. 2020 May;23(3):540-549. doi: 10.1007/s10120-019-01027-6. Epub 2020 Feb 18.

DOI:10.1007/s10120-019-01027-6
PMID:32072387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7165147/
Abstract

BACKGROUND

The clinical values of inflammatory and nutritional markers remained unclear for gastric cancer with neoadjuvant chemotherapy (NACT).

METHODS

The inflammatory, nutritional markers and their changes were analyzed for locally advanced gastric cancer with NACT. The predictive value was evaluated by the Cox proportional hazards regressions under three hypothesized scenarios. The nomograms including independent prognostic factors were plotted for survival prediction.

RESULTS

A total of 225 patients were included in the study. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index, and hemoglobin (Hgb) were significantly reduced, and the body mass index was significantly increased after NACT (all P < 0.05). The pre-NACT NLR [hazard ratio (HR) = 1.176, P = 0.059] showed a trend to correlate with the overall survival (OS) when only pre-NACT markers available; The post-NACT Hgb (HR = 0.982, P = 0.015) was the independent prognostic factor when only post-NACT markers available; The post-NACT Hgb (HR = 0.984, P = 0.025) and the change value of LMR (HR = 1.183, P = 0.036) were the independent prognostic factors when both pre- and post-NACT markers available. The nomogram had a similar Harrell's C-statistic compared to ypTNM stage (0.719 vs. 0.706).

CONCLUSION

For locally advanced gastric cancer, the NACT could significantly decrease some inflammatory markers. The pre-NACT NLR, the post-NACT Hgb and the change value of LMR had some values in survival prediction combined with age, sex, tumor location and the clinical stages under different clinical scenarios. The elevated initial NLR, the preoperative anemia and the greater change value of LMR implied a poor prognosis.

摘要

背景

新辅助化疗(NACT)后胃癌的炎症和营养标志物的临床价值仍不清楚。

方法

分析局部进展期胃癌 NACT 前后的炎症、营养标志物及其变化。在三种假设情况下,通过Cox 比例风险回归评估预测价值。绘制包括独立预后因素的列线图以进行生存预测。

结果

本研究共纳入 225 例患者。NACT 后,中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值、淋巴细胞与单核细胞比值(LMR)、全身免疫炎症指数和血红蛋白(Hgb)显著降低,体质指数显著升高(均 P<0.05)。仅在有 NACT 前标志物时,NACT 前 NLR[风险比(HR)=1.176,P=0.059]显示与总生存(OS)有一定的相关性;仅在有 NACT 后标志物时,NACT 后 Hgb(HR=0.982,P=0.015)是独立的预后因素;在有 NACT 前和 NACT 后标志物时,NACT 后 Hgb(HR=0.984,P=0.025)和 LMR 变化值(HR=1.183,P=0.036)是独立的预后因素。列线图与 ypTNM 分期的 Harrell's C 统计量相似(0.719 比 0.706)。

结论

对于局部进展期胃癌,NACT 可显著降低一些炎症标志物。在不同临床情况下,NACT 前 NLR、NACT 后 Hgb 和 LMR 变化值与年龄、性别、肿瘤部位和临床分期相结合,在生存预测方面具有一定价值。初始 NLR 升高、术前贫血和 LMR 变化值较大提示预后不良。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bb4/7165147/b3aa5089a8f4/10120_2019_1027_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bb4/7165147/b3aa5089a8f4/10120_2019_1027_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bb4/7165147/b3aa5089a8f4/10120_2019_1027_Fig1_HTML.jpg

相似文献

1
The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy.炎症和营养标志物在新辅助化疗和 D2 淋巴结清扫术治疗胃癌患者生存预测中的临床价值和应用。
Gastric Cancer. 2020 May;23(3):540-549. doi: 10.1007/s10120-019-01027-6. Epub 2020 Feb 18.
2
In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.在接受新辅助化疗的胃癌患者中,全身炎症反应指数是一种有用的预后指标。
Pathol Oncol Res. 2021 Oct 12;27:1609811. doi: 10.3389/pore.2021.1609811. eCollection 2021.
3
Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.炎症和营养标志物在晚期胃癌围手术期的预后意义。
BMC Cancer. 2023 Jan 3;23(1):5. doi: 10.1186/s12885-022-10479-6.
4
Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.外周静脉血血小板与淋巴细胞比值(PLR)预测 SOX 或 XELOX 方案新辅助化疗治疗胃癌患者的生存情况。
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819829485. doi: 10.1177/1533033819829485.
5
The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.新辅助治疗前后系统性免疫炎症标志物对乳腺癌患者病理完全缓解的预测价值:1994 例患者的回顾性研究。
Clin Transl Oncol. 2024 Jun;26(6):1467-1479. doi: 10.1007/s12094-023-03371-7. Epub 2024 Jan 8.
6
Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.中性粒细胞-淋巴细胞比值预测新辅助化疗治疗 III-IV 期胃癌的生存。
World J Surg Oncol. 2013 May 24;11:112. doi: 10.1186/1477-7819-11-112.
7
After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients.新辅助化疗后,血小板/淋巴细胞比值与胃癌患者的预后呈负相关。
J Clin Lab Anal. 2018 Jun;32(5):e22364. doi: 10.1002/jcla.22364. Epub 2017 Dec 18.
8
CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.CA724 预测新辅助化疗局部晚期胃癌患者的总生存期。
BMC Cancer. 2021 Jan 5;21(1):4. doi: 10.1186/s12885-020-07666-8.
9
Impact of dynamic changes of tumor marker in neoadjuvant chemotherapy-treated triple-negative gastric cancer patients: a multi-center study.新辅助化疗治疗三阴性胃癌患者肿瘤标志物动态变化的影响:一项多中心研究。
BMC Cancer. 2024 Sep 27;24(1):1188. doi: 10.1186/s12885-024-12937-9.
10
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.外周血中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值联合预测乳腺癌患者新辅助化疗后的病理完全缓解。
Breast. 2019 Apr;44:33-38. doi: 10.1016/j.breast.2018.12.014. Epub 2019 Jan 2.

引用本文的文献

1
Real world effectiveness of chemotherapy plus bevacizumab with immunotherapy in colorectal cancer.化疗联合贝伐单抗与免疫疗法在结直肠癌中的真实世界疗效
Sci Rep. 2025 Aug 9;15(1):29170. doi: 10.1038/s41598-025-13701-0.
2
Prognostic Value of Inflammatory Indices in Papillary Gastric Carcinoma with Different Proportions of Papillary Components.不同乳头成分比例的胃乳头状癌中炎症指标的预后价值
J Inflamm Res. 2025 Jul 15;18:9243-9259. doi: 10.2147/JIR.S532396. eCollection 2025.
3
Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis.

本文引用的文献

1
Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.白细胞增多和中性粒细胞增多作为 CAO/ARO/AIO-04 随机 3 期直肠癌试验中独立的预后免疫生物标志物预测临床结局。
Int J Cancer. 2019 Oct 15;145(8):2282-2291. doi: 10.1002/ijc.32274. Epub 2019 Apr 2.
2
The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data.术前 C 反应蛋白-白蛋白比值对根治性胃切除术后胃癌患者早期复发和化疗获益的预测价值:使用随机 III 期试验数据。
Gastric Cancer. 2019 Sep;22(5):1016-1028. doi: 10.1007/s10120-019-00936-w. Epub 2019 Feb 9.
3
接受新辅助化疗的胃癌患者中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值与预后的相关性:一项荟萃分析
BMC Gastroenterol. 2025 Jul 1;25(1):445. doi: 10.1186/s12876-025-04056-x.
4
Preoperative immune prognostic index predicts the prognosis and postoperative adjuvant chemotherapy benefits of esophageal squamous cell carcinoma after minimally invasive esophagectomy.术前免疫预后指数可预测微创食管切除术后食管鳞状细胞癌的预后及术后辅助化疗疗效。
BMC Gastroenterol. 2025 May 8;25(1):344. doi: 10.1186/s12876-025-03959-z.
5
Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients undergoing neoadjuvant chemotherapy: A systematic review and meta-analysis.中性粒细胞与淋巴细胞比值在接受新辅助化疗的胃癌患者中的预后价值:一项系统评价和荟萃分析
World J Gastrointest Oncol. 2024 Nov 15;16(11):4477-4488. doi: 10.4251/wjgo.v16.i11.4477.
6
Layer Analysis Based on RNA-Seq Reveals Molecular Complexity of Gastric Cancer.基于 RNA-Seq 的层分析揭示了胃癌的分子复杂性。
Int J Mol Sci. 2024 Oct 22;25(21):11371. doi: 10.3390/ijms252111371.
7
A Review of the Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Nonhematologic Malignancies.非血液系统恶性肿瘤中中性粒细胞与淋巴细胞比值的预后意义综述
Diagnostics (Basel). 2024 Sep 16;14(18):2057. doi: 10.3390/diagnostics14182057.
8
Development and validation of an individualized nomogram for gastric cancer patients treated with perioperative chemotherapy followed by radical surgery.接受围手术期化疗后行根治性手术的胃癌患者个体化列线图的开发与验证
Transl Gastroenterol Hepatol. 2024 Jun 17;9:39. doi: 10.21037/tgh-23-75. eCollection 2024.
9
Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.免疫检查点抑制剂治疗胃癌患者中炎症标志物 NLR、PLR 和 LMR 的预后价值:荟萃分析和系统评价。
Front Immunol. 2024 Jul 10;15:1408700. doi: 10.3389/fimmu.2024.1408700. eCollection 2024.
10
Development and validation of an inflammatory biomarkers model to predict gastric cancer prognosis: a multi-center cohort study in China.炎症生物标志物模型的建立和验证,以预测胃癌的预后:来自中国多中心队列研究。
BMC Cancer. 2024 Jun 10;24(1):711. doi: 10.1186/s12885-024-12483-4.
Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment.洗胃恶性细胞(yGL)和低血红蛋白血症(y贫血)作为新辅助治疗后胃癌肿瘤消退分级和预后预测的新系统
Anticancer Res. 2019 Feb;39(2):1019-1027. doi: 10.21873/anticanres.13208.
4
The Impact of Preoperative Underweight Status on Postoperative Complication and Survival Outcome of Gastric Cancer Patients: A Systematic Review and Meta-analysis.术前体重不足状态对胃癌患者术后并发症和生存结局的影响:系统评价和荟萃分析。
Nutr Cancer. 2018 Nov-Dec;70(8):1254-1263. doi: 10.1080/01635581.2018.1559937. Epub 2019 Jan 26.
5
Anaemia and its effects on tumour regression grade and survival following chemotherapy in adenocarcinoma of the oesophagus.贫血及其对食管腺癌化疗后肿瘤退缩分级和生存的影响。
J Gastrointest Oncol. 2018 Oct;9(5):797-805. doi: 10.21037/jgo.2018.06.05.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer.术前改良全身炎症评分对胃癌患者的预后意义。
Gastric Cancer. 2019 Mar;22(2):403-412. doi: 10.1007/s10120-018-0854-6. Epub 2018 Jul 7.
8
Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值能否有助于预测胃癌患者的淋巴结转移和作为有前途的预后标志物?肿瘤标志物回顾性研究。
Int J Surg. 2018 Aug;56:320-327. doi: 10.1016/j.ijsu.2018.06.037. Epub 2018 Jun 30.
9
Prognostic value of systemic immune-inflammation index in patients with gastric cancer.全身免疫炎症指数在胃癌患者中的预后价值
Chin J Cancer. 2017 Sep 12;36(1):75. doi: 10.1186/s40880-017-0243-2.
10
Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy.单核细胞与淋巴细胞比值可预测接受新辅助化疗的晚期胃癌患者的生存率。
Onco Targets Ther. 2017 Aug 10;10:4007-4016. doi: 10.2147/OTT.S140118. eCollection 2017.